Global Health EDCTP3 commits to supporting completion of EDCTP2-funded clinical trials affected by COVID-19 pandemic
Global Health EDCTP3 is supporting eight projects with trials initially funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2 programme) and affected by the COVID-19 pandemic.
The COVID-19 pandemic has severely impacted the global health scene, causing severe interruptions in public health services, restrictions of non-urgent medical care and diversion of already limited healthcare resources. In parallel, the pandemic also had a negative impact on global research efforts to combat infectious diseases, such as HIV, TB, malaria, respiratory infections, and poverty-related and neglected diseases.
In this context, clinical trials supported by the EDCTP2 programme were also affected and their implementation slowed down significantly.
As part of the 2023 Work Programme, Global Health EDCTP3 launched a specific call for proposals (HORIZON-JU-GH-EDCTP3-2023-01-02), with an indicative budget of €14 million in April 2023, to support the most affected projects and allow appropriate completion of corresponding trials.
Following evaluation of the 18 project proposals received, eight consortia have been awarded grants to complete trials in various diseases areas, including TB prevention in diabetic patients, evaluation of antimalarials, treatment of TB meningitis, leprosy chemoprophylaxis, and evaluation of new TB diagnostic strategies.
To learn more about the funded projects, click below:
| PROJECT | BUDGET | COORDINATOR |
|---|---|---|
Fortifying the automated smartphone-based Cough Audio classification for rapid triaGE testing for tuberculosis project. | €981 469,25 | Stellenbosch University (ZA) |
Clinical evaluation of AntimalarialS tri-therapy with AtovAquone-Proguanil for treatment of uncomplicated malaria in African children. | €1 499 996,25 | Bernhard-Nocht-Institut fuer Tropenmedizin (DE) |
Intensified tuberculosis treatment to reduce the high mortality of tuberculous meningitis in HIV-infected and uninfected patients. | €2 497 565,00 | Universite de Bordeaux (FR) |
Chemoprohylaxis for leprosy: comparing the effectiveness and feasibility of a community-based intervention to a health centre-based intervention in Ethiopia, Mozambique, and Tanzania. | €1 780 303,75 | Nederlandse Stichting voor Leprabestrijding (NE) |
Randomised Controlled Trial of Preventive Treatment of Latent Tuberculosis Infection in Patients with Diabetes Mellitus. | €2 337 586,25 | Stichting Radboud Universitair Medisch Centrum (NE) |
Efficacy and Safety of a newly registered Artemisinin-Based Combination (Pyronaridine-Artesunate -PYRAMAX®) for the treatment of uncomplicated malaria in African pregnant women – Extended. | €1 539 644,56 | Stichting Amsterdam UMC (NE) |
Evaluating a new stool-based qPCR for diagnosis of tuberculosis in children and people living with HIV. | €348 247,50 | Fundacion Privada Instituto de Salud Global Barcelona (ES) |
Preventing and delaying the development of diabetes in Africa: a randomised placebo -controlled double-blind phase iii trial of metformin in HIV-infected persons with pre-diabetes. | €1 811 067,50 | Fundacion Privada Instituto de Salud Global Barcelona (ES) |
Other projects funded under the Global Health EDCTP3 Work Programme 2023 are just starting. More information about them is available on the dedicated projects page.